With FAA | Without FAA | P-values | |
---|---|---|---|
(598, 29.2%) | (1448, 70.8%) | ||
Demographic Characteristics | |||
Female, n (%) | 520 (87.0) | 1209 (83.5) | 0.05 |
Age at the time of enrollment, years | 54.1 ± 12.6 | 54.4 ± 13.0 | 0.63 |
Disease duration, years | 8.5 ± 8.3 | 7.4 ± 7.0 | < 0.01 |
Disease duration < 1 year, n (%) | 99 (16.6) | 228 (15.8) | 0.69 |
Disease duration < 2 years, n (%) | 170 (28.5) | 399 (27.7) | 0.70 |
Disease duration < 3 years, n (%) | 200 (33.6) | 509 (35.3) | 0.47 |
Disease duration < 4 years, n (%) | 241 (40.4) | 622 (43.1) | 0.28 |
Disease duration < 5 years, n (%) | 273 (45.8) | 71 (49.6) | |
Disease duration ≥5 years, n (%) | 323 (54.2) | 727 (50.4) | 0.12 |
Body mass index, kg/m2 | 22.6 ± 3.6 | 22.6 ± 3.2 | 0.97 |
Current/ex-smoker, n (%) | 89 (14.9) | 217 (15.0) | 1.00 |
Presence of RA-associated lung diseases, n (%) | 21 (3.5) | 47 (3.3) | 0.79 |
Positive for rheumatoid factor, n (%) | 491 (85.1) | 1174 (83.5) | 0.38 |
Positive for anti-cyclic citrullinated peptide, n (%) | 404 (84.7) | 1046 (85.1) | 0.88 |
Radiographic damage | |||
Hand X-ray | |||
Erosion, n (%) | 197 (40.0) | 417 (34.8) | < 0.05 |
Joint space narrowing, n (%) | 226 (45.8) | 555 (46.5) | 0.83 |
Feet X-ray | |||
Erosion, n (%) | 153 (36.7) | 247 (29.1) | < 0.01 |
Joint space narrowing, n (%) | 107 (25.7) | 224 (26.5) | 0.79 |
Medication | |||
Current glucocorticoid use, n (%) | 497 (83.1) | 1169 (80.7) | 0.21 |
Daily dose (prednisolone equivalent), mg | 5.2 ± 10.7 | 4.3 ± 4.2 | < 0.01 |
Current use of MTX, n (%) | 567 (94.8) | 1337 (92.3) | 0.05 |
Previous use of bDMARDs, n (%) | 145 (24.2) | 233 (16.1) | < 0.01 |
Disease activity | |||
Swollen joint count (44 joints examined) | 8.9 ± 6.8 | 3.9 ± 4.4 | < 0.01 |
Tender joint count (44 joints examined) | 11.9 ± 8.6 | 4.9 ± 5.0 | < 0.01 |
Patients Global Assessment score (1–10 mm) | 6.7 ± 2.3 | 5.7 ± 2.6 | < 0.01 |
Evaluator’s Global Assessment score (1–10 mm) | 6.0 ± 5.2 | 5.2 ± 2.6 | < 0.01 |
ESR, mm/h | 48.8 ± 29.2 | 41.3 ± 27.2 | < 0.01 |
CRP, mg/dL | 2.6 ± 3.3 | 1.7 ± 2.3 | < 0.01 |
DAS28-ESR score | 5.6 ± 1.4 | 4.7 ± 1.5 | < 0.01 |
DAS28-CRP score | 4.9 ± 1.4 | 4.0 ± 1.5 | < 0.01 |
SDAI score | 30.3 ± 14.3 | 21.3 ± 12.8 | < 0.01 |
CDAI score | 27.8 ± 13.2 | 19.7 ± 11.9 | < 0.01 |
RAPID3 score | 15.9 ± 6.0 | 12.4 ± 6.6 | < 0.01 |
The proportion of patients with remission | |||
DAS28-ESR, n (%) | 21 (3.5) | 153 (10.7) | < 0.01 |
DAS28-CRP, n (%) | 38 (6.4) | 305 (21.4) | < 0.01 |
SDAI, n (%) | 8 (1.3) | 112 (7.7) | < 0.01 |
CDAI, n (%) | 3 (0.5) | 69 (4.8) | < 0.01 |
RAPID3, n (%) | 12 (2.0) | 128 (8.9) | < 0.01 |
Boolean-based criteria, n (%) | 5 (0.8) | 82 (5.8) | < 0.01 |